Related Experiment Video

Updated: Nov 14, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

382

Factors determining acceptance of illness in patients with arterial hypertension and comorbidities

Magdalena Bijak1, Agnieszka Olszanecka1, Ewa Pałczyńska1

  • 11st Department of Cardiology, Interventional Electrocardiology and Arterial Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

Kardiologia Polska
|March 10, 2021
PubMed

Insights

Illness acceptance in patients with arterial hypertension (AH) is linked to fewer comorbidities and shorter disease duration. Higher acceptance correlates with better health outcomes, impacting treatment and patient well-being.

Area of Science:

  • Cardiology
  • Psychology
  • Public Health

Background:

  • Arterial hypertension (AH) is a prevalent chronic disease with significant patient burden.
  • AH often presents with comorbidities like metabolic disorders and complications from polypharmacy.
  • Managing hypertension requires indefinite treatment, increasing risks of adverse drug events.

Purpose of the Study:

  • To investigate factors influencing illness acceptance in patients with arterial hypertension.
  • To understand the relationship between illness acceptance and disease characteristics.

Main Methods:

  • A study involving 532 patients diagnosed with AH.
  • Utilized the Acceptance of Illness Scale and a custom questionnaire.
  • Classified illness acceptance into high (30-40), average (19-29), or low (8-18) levels.

Main Results:

  • High illness acceptance was observed in 45% of participants; average acceptance in 46%.
  • Disparities noted in AH duration, disease count, mental disorders, and medication use.
  • Patients with high acceptance had fewer cardiovascular diseases and shorter AH duration.

Conclusions:

  • Illness acceptance levels correlate with disease duration, number of comorbidities, and medication count.
  • Higher illness acceptance is associated with a reduced number of cardiovascular diseases.
  • Disease duration was shorter in patients with higher illness acceptance.
Abstract

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.8K
Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.5K

Related Concept Videos

Factors affecting Blood pressure01:28

Factors affecting Blood pressure

Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
5.8K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.4K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
273
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
186
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
134
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
317